Abstract 200P
Background
Transarterial chemoembolization (TACE) is the first-line treatment for intermediate-stage Hepatocellular carcinoma (HCC) patients. However, predicting the Survival of hepatocellular carcinoma (HCC) patients receiving TACE remains challenging.
Methods
This retrospective study included 1805 HCC patients receiving TACE. Each patient was randomized to a training set (n = 1264) and a validation set (n = 541). We investigated prognostic factors in the training set and developed an easily applicable ALFP (ALBI grade, AFP, and Prothrombin time) score, which was evaluated in the validation set.
Results
We built the ALFP score using baseline ALBI grade 2 or 3 (HR 1.301, 95% CI 1.073-1.577,p = 0.007) and AFP ≥ 100 ng/ml (HR 1.328, 95% CI 1.133-1.557, p < 0.001)and PT 13.1 s (HR 1.262, 95% CI 1.047-1.521, p=0.015), which were identified as unfavorable prognosis factors in a multivariate analysis. The median OS in patients with ALFP scores of 0, 1, 2, and 3 points was 50.1 months (95% CI NA), 33.6months (95% CI 27.4–39.8), and 20.4months (95% CI 18.0–22.8), and 12.7 months (95% CI 10.2–15.2), respectively; the difference was statistically significant (p < 0.001).the result were confirmed in the validation set(The median OS ,0/1/2/3 points = 42.5/32.6/20.4 /13.0 months, p < 0.0019).
Conclusions
The ALFP score can predict the prognosis of HCC patients receiving TACE.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Xiong Chen.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
485P - LDCT lung cancer screening of never-smokers meta-analysis subgroup analysis: Adenocarcinoma is the highly predictive histology identified in never-smokers
Presenter: Sai-Hong Ou
Session: Poster Display
Resources:
Abstract
486P - Fiscal feasibility and implications of integrating lung cancer screening into Hong Kong’s healthcare system
Presenter: Herbert Ho Fung Loong
Session: Poster Display
Resources:
Abstract
487P - Evaluating the performance of the USPSTF lung cancer screening guidelines in an Asian population of lung cancer patients
Presenter: Jian Wei Tan
Session: Poster Display
Resources:
Abstract
488P - Pulmonary ground glass opacity lesions: Immune ecosystem and its clinical relevances of early-stage lung adenocarcinoma
Presenter: Shensi Shen
Session: Poster Display
Resources:
Abstract
489TiP - BGB-LC-202 (NCT05577702): Phase II Umbrella study of tislelizumab (TIS) monotherapy and TIS-based immunotherapy combinations +/- chemotherapy (CT) as neoadjuvant treatment in Chinese patients (pts) with resectable stage II to IIIA non-small cell lung cancer (NSCLC)
Presenter: Wentao Yu
Session: Poster Display
Resources:
Abstract
491P - Furmonertinib as adjuvant therapy for elderly patients in resected EGFR-mutated non-small cell lung cancer: A double-center, real-world experience
Presenter: Ziheng Wu
Session: Poster Display
Resources:
Abstract
492P - Penpulimab-based combination neoadjuvant/adjuvant therapy for patients with resectable locally advanced non-small cell lung cancer: Preliminary results from a phase II study (ALTER-L043)
Presenter: Changli Wang
Session: Poster Display
Resources:
Abstract
493P - The prognostic value of 4L lymph node dissection in left-sided operable non-small cell lung cancer: A systematic review and meta-analysis
Presenter: Lei Peng
Session: Poster Display
Resources:
Abstract
495P - Intrinsic STING of CD8+T cells regulates self-metabolic reprogramming and exerts anti-tumor effects
Presenter: Qiuli Xu
Session: Poster Display
Resources:
Abstract
496P - Fruquintinib plus sintilimab in patients (pts) with advanced non-small cell lung cancer (NSCLC) with PD-L1-positive expression: A multicenter, single-arm phase II study
Presenter: Shun Lu
Session: Poster Display
Resources:
Abstract